Brain Tumor Grades and Diagnosis

Diagnosis usually starts with a neurological exam. A doctor checks your reflexes, muscle strength, vision, eye and mouth movement, coordination, balance, and alertness. This exam alone cannot diagnose a tumor. It helps point to which part of the brain may be affected. That then guides what imaging to order.

MRI is the best tool for finding brain and spinal cord tumors. It is usually done twice in one visit. The first pass has no contrast. The second comes after a contrast dye called gadolinium is injected into a vein. The dye highlights areas where a tumor may be. Tumors often show up differently than normal tissue. CT scans are used when MRI is not possible. They are also used when speed matters most, such as in an emergency. PET scans can help tell an active tumor apart from scar tissue left over after treatment.

Imaging can show that something is there, but not always what it is. Confirming a diagnosis usually requires a tissue sample, examined under a microscope by a pathologist. There are two main ways to get one.

A stereotactic needle biopsy uses imaging to guide a thin needle to the tumor. It removes a small sample. This is often used when the tumor sits in a location too risky for open surgery. The alternative is a craniotomy. This is open surgery to remove tissue, sometimes the whole tumor, while you are under general anesthesia. During a craniotomy, a pathologist can often give a preliminary answer while the surgery is still happening. That can help guide how much tissue the surgeon removes.

Modern brain tumor diagnosis goes beyond what a tumor looks like under a microscope. Genetic testing on the tissue sample looks for specific changes that affect treatment and outlook.

An IDH gene mutation is linked to a better prognosis. It also helps define which type of tumor you have. It is now part of how gliomas are classified, not just an extra detail. MGMT promoter methylation is a marker. It predicts how well a tumor is likely to respond to certain chemotherapy drugs. A 1p/19q codeletion is a specific loss of genetic material. It is used to identify oligodendrogliomas. This separates them from other gliomas that look similar under a microscope.

Once type and molecular features are known, doctors assign a grade from 1 to 4. The current classification system, updated in 2021, uses these numbers instead of the Roman numerals I through IV used in the past. Grade reflects how abnormal the cells look. It also reflects how fast the tumor is likely to grow. It does not reflect how far the tumor has spread. This is different from most other cancers, which use a stage based on spread instead.

Grade 1 tumors grow slowly and often have a good outlook, sometimes cured completely with surgery. Grade 2 tumors also grow slowly. They tend to grow into surrounding tissue over time. They can progress to a higher grade later. Grade 3 tumors grow faster and are considered malignant. Grade 4 tumors, including glioblastoma, grow the fastest and are the hardest to control. Genetic markers can also change the effective grade. Certain molecular changes can raise an otherwise lower-grade-looking tumor into a higher-grade category. That happens because the biology behaves more aggressively than the appearance alone suggests.

Type, molecular markers, and grade work together. No single piece alone determines your treatment options or what to reasonably expect. Two tumors can look identical under a basic microscope exam. They can still behave very differently once their genetic features are known. This is why molecular testing has become a standard part of diagnosis, not an optional extra.

• What is the exact type and grade of my tumor?
• Which molecular markers were tested — IDH mutation, MGMT methylation, 1p/19q codeletion — and what did they show?
• How do these results change my treatment options or outlook?
• Will I need another biopsy if the tumor changes over time?

• American Cancer Society — How Are Brain and Spinal Cord Tumors Diagnosed?
• CAP — Updates in Glioma and Meningioma Classification: WHO 2021 & New Entities